These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20398037)

  • 1. Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases.
    Rosenthal MA; Davidson P; Rolland F; Campone M; Xue L; Han TH; Mehta A; Berd Y; He W; Lombardi A
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):42-8. PubMed ID: 20398037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
    Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
    Ueda T; Suzuki H; Akakura K; Ishihara M; Kamiya N; Komiya A; Shimbo M; Suyama T; Sakamoto S; Ichikawa T
    Hinyokika Kiyo; 2006 Jul; 52(7):515-21. PubMed ID: 16910582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
    Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
    Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
    Taue R; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
    Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
    Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
    Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
    J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.